Taysha Gene Therapies, Inc.
TSHA- Exchange
- Nasdaq
- Industry
- Biological Products, (No Diagnostic Substances)
- SEC CIK
- 0001806310
No open-market purchases or sales by Taysha Gene Therapies, Inc. insiders were filed in the last 90 days; 204 institutions reported holding it in 13F filings for Q3 2026, worth $1.54B in total; no superinvestor holds it.
Key figures
- Market capClose on Nov 20, 2026
- $1.21B
- Insider buysOpen market, last 90 days
- 0
- Insider sellsOpen market, last 90 days
- 0
- 13F holdersQ3 2026, +2 vs. previous quarter
- 204
- 13F valueReported value at the end of Q3 2026
- $1.54B
- Superinvestors holdingAt the end of Q3 2026
- 0
Price chart
Financials
See financial statementsFrom SEC filings, in USD.
- Revenue, FY2025
- $9.77M
- +17.3% year over year
- Net income, FY2025
- -$109.0M
- No comparable prior period
- Free cash flow, FY2025
- -$93.8M
- No comparable prior period
- Revenue, Q3 FY2026
- $0
- No comparable prior period
Revenue flow, FY2025
Green is profit; orange is costs, expenses and taxes. Percentages are shares of revenue.
Net loss for FY2025: $109.0M (1115.3% of revenue).
Short interest
See short dataFrom FINRA, settlement date Oct 30, 2026.
- Short interest
- 53.5M
- Shares sold short
- Change
- +2.23M
- +4.4% vs. previous
- Days to cover
- 14.76
- At average daily volume
Superinvestors holding TSHA, Q3 2026
Go to the superinvestors tabNo superinvestor reported holding TSHA at the end of Q3 2026.
Latest insider trades
See all insider tradesOpen-market purchases and sales by Taysha Gene Therapies, Inc. insiders from Form 4, newest first.
| Filed (ET) | Trade date | Filing delay | Insider | Transaction | Shares | Avg price | Value | Holding change | Flags |
|---|---|---|---|---|---|---|---|---|---|
| Jul 10, 2026 (view filing)6:54 PM ET | Jul 10 | Same day | Nagendran SukumarPresident and Head of R&D | SSale | −200.0K | $6.24 | −$1.25M | −17.6%936.4K after | 10b5-1 |
| Apr 13, 2026 (view filing) | Apr 10 | 3 days | Nagendran SukumarPresident and Head of R&D | SSale | −200.0K | $4.46 | −$892.0K | −15.0%1.14M after | 10b5-1 |
| Feb 6, 2026 (view filing) | Feb 4 | 2 days | Alam KamranCHIEF FINANCIAL OFFICER | SSale | −1.66K | $4.52 | −$7.48K | −0.1%1.44M after | |
| Jan 27, 2026 (view filing) | Jan 23-26 | 4 days | Alam KamranCHIEF FINANCIAL OFFICER | SSale | −102.8K | $4.72 | −$485.0K | −6.6%1.44M after | 2 lots |
| Jan 27, 2026 (view filing) | Jan 23-26 | 4 days | Nagendran SukumarPresident and Head of R&D | SSale | −116.0K | $4.72 | −$547.5K | −8.1%1.32M after | 2 lots |
| Jan 27, 2026 (view filing) | Jan 23-26 | 4 days | Nolan Sean P.Chief Executive Officer | SSale | −178.1K | $4.72 | −$840.2K | −5.8%2.91M after | 2 lots |
| Jan 14, 2026 (view filing) | Jan 12 | 2 days | Nagendran SukumarPresident and Head of R&D | SSale | −200.0K | $4.71 | −$942.0K | −16.6%1.01M after | 10b5-1 |
| Dec 1, 2025 (view filing) | Nov 28-Dec 1 | 3 days | Nagendran SukumarPresident and Head of R&D | SSale | −370.2K | $4.58 | −$1.70M | −26.9%1.01M after | 2 lots |
| Sep 12, 2025 (view filing) | Sep 10 | 2 days | Nagendran SukumarPresident and Head of R&D | SSale | −200.0K | $3.23 | −$646.0K | −16.6%1.01M after | 10b5-1 |
| Aug 22, 2025 (view filing) | Aug 21 | 1 day | Nagendran SukumarPresident and Head of R&D | SSale | −57.1K | $2.85 | −$162.6K | −4.7%1.17M after |
Top 10 13F holders, Q3 2026
See all 204 holdersThe largest institutional positions in Taysha Gene Therapies, Inc. at the end of Q3 2026; share changes are against Q2 2026.
| Institution | Shares | Value | % of portfolio | Change in shares | Action |
|---|---|---|---|---|---|
| Ra Capital Management, L.P. | 30,435,190 | $148.2M | 1.49% | +6,879,542+29.2% | Added |
| Goldman Sachs Group Inc | 25,115,519 | $122.3M | 0.01% | +2,402,401+10.6% | Added |
| Avoro Capital Advisors LLC | 23,888,888 | $116.3M | 1.20% | 00.0% | Unchanged |
| BlackRock, Inc. | 22,651,999 | $110.3M | 0.00% | +1,960,072+9.5% | Added |
| Vestal Point Capital, LP | 18,045,000 | $87.9M | 2.27% | −1,370,000−7.1% | Reduced |
| Morgan Stanley | 15,722,735 | $76.6M | 0.00% | −764,744−4.6% | Reduced |
| RTW Investments, LP | 13,560,258 | $66.0M | 0.67% | 00.0% | Unchanged |
| FMR LLC | 13,558,965 | $66.0M | 0.00% | +222,552+1.7% | Added |
| Vanguard Capital Management LLC | 12,540,069 | $61.1M | 0.00% | +61,474+0.5% | Added |
| State Street Corp | 11,380,707 | $55.4M | 0.00% | −41,213−0.4% | Reduced |
Holders of 5% or more of TSHA
See all 7 holders and filingsHolders whose latest Schedule 13D or 13G filing reports 5% or more of Taysha Gene Therapies, Inc..
| Holder | Latest form | Stake | Change | First filed | Latest filing | Filing |
|---|---|---|---|---|---|---|
| Ra Capital Management, L.P. | 13G/A | 9.90%32.8M shares | 0.00 ppfrom 9.90% | Aug 25, 20237 filings | Nov 16, 2026 | SEC |
| Manning Paul B | 13D/A | 9.80%25.6M shares | – | Nov 2, 20223 filings | Jun 3, 2025 | SEC |
| RTW Investments, LP | 13G/A | 7.00%20.7M shares | −1.30 ppfrom 8.30% | Feb 14, 20246 filings | May 15, 2026 | SEC |
| BlackRock, Inc. | 13G/A | 6.50%17.9M shares | +1.30 ppfrom 5.20% | Oct 22, 20244 filings | Jan 21, 2026 | SEC |
| Vestal Point Capital, LP | 13G/A | 6.30%18.0M shares | +1.30 ppfrom 5.00% | Feb 17, 20262 filings | May 15, 2026 | SEC |